Kaposi's Sarcoma Associated Herpes Virus (KSHV) induced COX-2: A key factor in latency, inflammation, angiogenesis, cell survival and invasion

PLoS Pathogens

Volumn 6, Issue 2, 2010, Pages

  Sharma Walia, Neelam ^a   Paul, Arun George ^a   Bottero, Virginie ^a   Sadagopan, Sathish ^a   Veettil, Mohanan Valiya ^a   Kerur, Nagaraj ^a   Chandran, Bala ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; GROWTH FACTOR; PROSTAGLANDIN E2;

ANGIOGENESIS; ARTICLE; CELL INVASION; CELL SURVIVAL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; INFLAMMATION; KAPOSI SARCOMA; LATENT PERIOD; NONHUMAN; CELL ADHESION; CELL SEPARATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS LATENCY; WESTERN BLOTTING;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

BLOTTING, WESTERN; CELL ADHESION; CELL SEPARATION; CYCLOOXYGENASE 2; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, KAPOSI; VIRUS LATENCY;

EID: 77649258068     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000777     Document Type: Article

References (97)

1. Boshoff C, Weiss RA (1998) Kaposi's sarcoma-associated herpesvirus. Adv Cancer Res 75: 57-86.
2. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, et al. (1999) Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96: 4546-4551.
3. Fidler IJ, Singh RK, Yoneda J, Kumar R, Xu L, et al. (2000) Critical determinants of neoplastic angiogenesis. Cancer J 6 Suppl 3: S225-236.
4. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
5. Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, et al. (2007) Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res 67: 4042-4051.
6. Sadagopan S, Sharma-Walia N, Veettil MV, Bottero V, Levine R, et al. (2009) Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. J Virol 83: 3342-3364.
7. McAllister SC, Hansen SG, Ruhl RA, Raggo CM, DeFilippis VR, et al. (2004) Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. Blood 103: 3465-3473.
8. Di Bartolo DL, Cannon M, Liu YF, Renne R, Chadburn A, et al. (2008) KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 111: 4731-4740.
9. Boshoff C, Weiss RA (1997) Aetiology of Kaposi's sarcoma: current understanding and implications for therapy. Mol Med Today 3: 488-494.
10. Blackbourn DJ, Lennette E, Klencke B, Moses A, Chandran B, et al. (2000) The restricted cellular host range of human herpesvirus 8. Aids 14: 1123-1133.
11. Hayward GS (2003) Initiation of angiogenic Kaposi's sarcoma lesions. Cancer Cell 3: 1-3.
12. Qian LW, Xie J, Ye F, Gao SJ (2007) Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol 81: 7001-7010.
13. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, et al. (1996) Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 93: 14862-14867.
14. Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, et al. (1997) Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 71: 839-842.
15. Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, et al. (2003) Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 3: 131-143.
16. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR (2000) Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629-4637.
17. Moore PS, Chang Y (2001) Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 356: 499-516.
18. McCormick C, Ganem D (2005) The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307: 739-741.
19. Murphy PM (1997) Pirated genes in Kaposi's sarcoma. Nature 385: 296-297, 299.
20. Milligan S, Robinson M, O'Donnell E, Blackbourn DJ (2004) Inflammatory cytokines inhibit Kaposi's sarcoma-associated herpesvirus lytic gene transcription in in vitro-infected endothelial cells. J Virol 78: 2591-2596.
21. Boshoff C, Gao SJ, Healy LE, Matthews S, Thomas AJ, et al. (1998) Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 91: 1671-1679.
22. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, et al. (1997) Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71: 715-719.
23. Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, et al. (1998) A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol 72: 8309-8315.
24. McClure LV, Sullivan CS (2008) Kaposi's sarcoma herpes virus taps into a host microRNA regulatory network. Cell Host Microbe 3: 1-3.
25. Naranatt PP, Krishnan HH, Svojanovsky SR, Bloomer C, Mathur S, et al. (2004) Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res 64: 72-84.
26. Sharma-Walia N, Raghu H, Sadagopan S, Sivakumar R, Veettil MV, et al. (2006) Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol 80: 6534-6552.
27. Shelby BD, LaMarca HL, McFerrin HE, Nelson AB, Lasky JA, et al. (2007) Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells. Virol J 4: 87.
28. Brinkmann MM, Pietrek M, Dittrich-Breiholz O, Kracht M, Schulz TF (2007) Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. J Virol 81: 42-58.
29. Vane JR, Botting RM (1998) Anti-inflammatory drugs and their mechanism of action. Inflamm Res 47 Suppl 2: S78-87.
30. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182.
31. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO (2002) Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24: 792-799.
32. Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436.
33. Dempke W, Rie C, Grothey A, Schmoll HJ (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127: 411-417.
34. Sharma-Walia N, Krishnan HH, Naranatt PP, Zeng L, Smith MS, et al. (2005) ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J Virol 79: 10308-10329.
35. Sharma-Walia N, Naranatt PP, Krishnan HH, Zeng L, Chandran B (2004) Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J Virol 78: 4207-4223.
36. Tiscornia G, Singer O, Verma IM (2006) Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc 1: 234-240.
37. Sivakumar R, Sharma-Walia N, Raghu H, Veettil MV, Sadagopan S, et al. (2008) Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol 82: 1759-1776.
38. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related bodycavity-based lymphomas. N Engl J Med 332: 1186-1191.
39. Ganem D (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 1: 273-296.
40. Cornelissen M, van der Kuyl AC, van den Burg R, Zorgdrager F, van Noesel CJ, et al. (2003) Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer 3: 7.
41. Krishnan HH, Naranatt PP, Smith MS, Zeng L, Bloomer C, et al. (2004) Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol 78: 3601-3620.
42. An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, et al. (2006) Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 80: 4833-4846.
43. Jiang XH, Lam SK, Lin MC, Jiang SH, Kung HF, et al. (2002) Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway. Oncogene 21: 6113-6122.
44. He Q, Luo X, Jin W, Huang Y, Reddy MV, et al. (2008) Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. Oncogene 27: 2656-2660.
45. von Rahden BH, Stein HJ, Puhringer F, Koch I, Langer R, et al. (2005) Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 65: 5038-5044.
46. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839.
47. Overall CM, Kleifeld O (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94: 941-946.
48. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES (2004) The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50: 87-100.
49. Pantanowitz L, Dezube BJ, Hernandez-Barrantes S, Tahan SR, Dabbous MK (2006) Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol 33: 793-798.
50. Ridley AJ (2001) Rho GTPases and cell migration. J Cell Sci 114: 2713-2722.
51. Burridge K, Wennerberg K (2004) Rho and Rac take center stage. Cell 116: 167-179.
52. Veettil MV, Sharma-Walia N, Sadagopan S, Raghu H, Sivakumar R, et al. (2006) RhoA-GTPase facilitates entry of Kaposi's sarcoma-associated herpesvirus into adherent target cells in a Src-dependent manner. J Virol 80: 11432-11446.
53. Dormond O, Bezzi M, Mariotti A, Ruegg C (2002) Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 277: 45838-45846.
54. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E (2007) COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol 104: 320-325.
55. Baoping Y, Guoyong H, Jieping Y, Zongxue R, Hesheng L (2004) Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line. Dig Dis Sci 49: 948-953.
56. Sadagopan S, Sharma-Walia N, Veettil MV, Raghu H, Sivakumar R, et al. (2007) Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. J Virol 81: 3949-3968.
57. Ambrus JL, Stoll HL, Klein EA, Karakousis CP, Stadler S (1992) Increased prostaglandin E2 and cAMP phosphodiesterase levels in Kaposi's sarcoma-a virus against host defense mechanism. Res Commun Chem Pathol Pharmacol 78: 249-252.
58. Rossiello L, Ruocco E, Signoriello G, Micheli P, Rienzo M, et al. (2007) Evidence of COX-1 and COX-2 expression in Kaposi's sarcoma tissues. Eur J Cancer 43: 1232-1241.
59. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, et al. (2001) Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3: 53-61.
60. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, et al. (2004) Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 36: 683-685.
61. Groger M, Loewe R, Holnthoner W, Embacher R, Pillinger M, et al. (2004) IL-3 induces expression of lymphatic markers Prox-1 and podoplanin in human endothelial cells. J Immunol 173: 7161-7169.
62. Inoue H, Takamori M, Shimoyama Y, Ishibashi H, Yamamoto S, et al. (2002) Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 136: 287-295.
63. Wang D, Mann JR, DuBois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128: 1445-1461.
64. Lee DC, Chua DT, Wei WI, Sham JS, Lau AS (2007) Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma. Biomed Pharmacother 61: 520-526.
65. Takeshita H, Yoshizaki T, Miller WE, Sato H, Furukawa M, et al. (1999) Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 73: 5548-5555.
66. Lu J, Chua HH, Chen SY, Chen JY, Tsai CH (2003) Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 63: 256-262.
67. Chung TW, Moon SK, Lee YC, Kim JG, Ko JH, et al. (2002) Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. Arch Biochem Biophys 408: 147-154.
68. Mastroianni CM, Liuzzi GM (2007) Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 13: 449-459.
69. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, et al. (2004) Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 94: 664-670.
70. Koskivirta I, Rahkonen O, Mayranpaa M, Pakkanen S, Husheem M, et al. (2006) Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol 126: 335-342.
71. Chirco R, Liu XW, Jung KK, Kim HR (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25: 99-113.
72. Yao L, Salvucci O, Cardones AR, Hwang ST, Aoki Y, et al. (2003) Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood 102: 3900-3905.
73. Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, et al. (2003) A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcomaassociated herpesvirus latency. Nat Med 9: 300-306.
74. Ottinger M, Christalla T, Nathan K, Brinkmann MM, Viejo-Borbolla A, et al. (2006) Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J Virol 80: 10772-10786.
75. Lim K, Han C, Xu L, Isse K, Demetris AJ, et al. (2008) Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res 68: 553-560.
76. Sawasdikosol S, Pyarajan S, Alzabin S, Matejovic G, Burakoff SJ (2007) Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway. J Biol Chem 282: 34693-34699.
77. Pham L, Bezouglaia O, Camargo PM, Nervina JM, Tetradis S (2007) Prostanoids induce egr1 gene expression in cementoblastic OCCM cells. J Periodontal Res 42: 486-493.
78. Frias MA, Rebsamen MC, Gerber-Wicht C, Lang U (2007) Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. Cardiovasc Res 73: 57-65.
79. Buchanan FG, DuBois RN (2006) Connecting COX-2 and Wnt in cancer. Cancer Cell 9: 6-8.
80. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, et al. (2005) Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65: 6275-6281.
81. Yamaki T, Endoh K, Miyahara M, Nagamine I, Thi Thu Huong N, et al. (2004) Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Cancer Lett 214: 115-120.
82. Mochizuki-Oda N, Mori K, Negishi M, Ito S (1991) Prostaglandin E2 activates Ca2+ channels in bovine adrenal chromaffin cells. J Neurochem 56: 541-547.
83. Micali A, Medici N, Sottile A, Venza M, Venza I, et al. (1996) Prostaglandin E2 induction of binding activity to CRE and AP-2 elements in human T lymphocytes. Cell Immunol 174: 99-105.
84. Liu XH, Kirschenbaum A, Lu M, Yao S, Dosoretz A, et al. (2002) Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277: 50081-50086.
85. Wang X, Klein RD (2007) Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol Carcinog 46: 912-923.
86. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, et al. (2004) Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 64: 7439-7446.
87. Bradbury D, Clarke D, Seedhouse C, Corbett L, Stocks J, et al. (2005) Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 280: 29993-30000.
88. Chuang PC, Sun HS, Chen TM, Tsai SJ (2006) Prostaglandin E2 induces fibroblast growth factor 9 via EP3-dependent protein kinase Cdelta and Elk-1 signaling. Mol Cell Biol 26: 8281-8292.
89. George RJ, Sturmoski MA, Anant S, Houchen CW (2007) EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 83: 112-120.
90. Ye FC, Zhou FC, Xie JP, Kang T, Greene W, et al. (2008) Kaposi's sarcomaassociated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J Virol 82: 4235-4249.
91. Cai Q, Lan K, Verma SC, Si H, Lin D, et al. (2006) Kaposi's sarcomaassociated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. J Virol 80: 7965-7975.
92. Lan K, Kuppers DA, Robertson ES (2005) Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway. J Virol 79: 3468-3478.
93. DeWitt DL (1999) Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55: 625-631.
94. Sun Q, Liu Q, Zheng Y, Cao X (2008) Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol 45: 2929-2936.
95. Manning DS, Sheehan KM, Byrne MF, Kay EW, Murray FE (2007) Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment. J Gastroenterol Hepatol 22: 1633-1637.
96. Duff M, Stapleton PP, Mestre JR, Maddali S, Smyth GP, et al. (2003) Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma. Ann Surg Oncol 10: 305-313.
97. Nakanishi Y, Kamijo R, Takizawa K, Hatori M, Nagumo M (2001) Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur J Cancer 37: 1570-1578.